Logotype for Apogee Therapeutics Inc

Apogee Therapeutics (APGE) investor relations material

Apogee Therapeutics Stifel Virtual Immunology and Inflammation Forum summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Apogee Therapeutics Inc
Stifel Virtual Immunology and Inflammation Forum summary16 Sep, 2025

Key presentations and data highlights

  • Presented three abstracts at EADV, including a late breaker with new phase 2 data for an IL-13 antibody in atopic dermatitis (AD).

  • Phase 2a data showed 66.9% EZ75 response and significant itch relief as early as one week, with only four dosing days.

  • Safety profile aligned with existing therapies; conjunctivitis rates similar to Dupixent and no injection site reactions reported.

  • Ongoing phase 2b study is testing three doses, with a mid-2026 readout planned.

  • Maintenance study will report in the first half of next year, focusing on sustained response with quarterly or semiannual dosing.

Market landscape and competitive positioning

  • Biologic market for AD is growing rapidly, with 25% overall growth and 48% increase in new-to-brand prescriptions year-over-year.

  • Recent launches of Eblis and Nimluvio have outperformed previous benchmarks in their first year.

  • Despite a crowded market, frontline therapy remains dominated by Dupixent, with new entrants mainly competing in later lines.

  • Market research suggests strong physician interest in a new therapy with a quarterly dosing schedule and efficacy comparable or superior to current options.

Forward-looking statements and development plans

  • Phase 2b and maintenance studies are progressing, with no safety concerns reported.

  • Combination therapy approach is being pursued, with a head-to-head study ongoing and readout expected in the second half of next year.

  • Company is prioritizing atopic dermatitis but also planning expansion into respiratory indications, starting with asthma.

  • Strong cash position ($620M) provides runway into 2028, supporting late-stage development and expansion plans.

  • Plans to launch the lead therapy as a monotherapy in AD by 2029, with additional expansion and combination data to be announced.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Apogee Therapeutics earnings date

Logotype for Apogee Therapeutics Inc
Q3 202512 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Apogee Therapeutics earnings date

Logotype for Apogee Therapeutics Inc
Q3 202512 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Apogee Therapeutics Inc. (APGE) is a biotechnology company engaged in the development of differentiated biologics for the treatment of various inflammatory and immunology (I&I) diseases, including atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and other conditions with high unmet medical needs. The company's approach is focused on creating best-in-class therapies that aim to improve upon the current standard of care for these conditions. The company is headquartered in San Francisco, California, and Waltham, Massachusetts, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage